William Blair Forecasts MaxCyte’s Q1 Earnings (NASDAQ:MXCT)

MaxCyte, Inc. (NASDAQ:MXCT) – Analysts at William Blair issued their Q1 2026 EPS estimates for shares of MaxCyte in a report issued on Wednesday, March 12th. William Blair analyst M. Larew anticipates that the company will post earnings of ($0.09) per share for the quarter. The consensus estimate for MaxCyte’s current full-year earnings is ($0.42) per share. William Blair also issued estimates for MaxCyte’s Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.30) EPS.

A number of other equities analysts also recently issued reports on the company. BTIG Research set a $6.00 price target on MaxCyte and gave the stock a “buy” rating in a research report on Wednesday. Stifel Nicolaus dropped their price target on shares of MaxCyte from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday.

MaxCyte Stock Performance

Shares of MaxCyte stock opened at $3.18 on Thursday. MaxCyte has a fifty-two week low of $2.76 and a fifty-two week high of $5.26. The company has a market cap of $336.95 million, a P/E ratio of -9.35 and a beta of 1.35. The firm has a 50-day simple moving average of $4.21 and a two-hundred day simple moving average of $3.98.

Institutional Trading of MaxCyte

Large investors have recently made changes to their positions in the company. Cadian Capital Management LP boosted its stake in MaxCyte by 14.1% during the 4th quarter. Cadian Capital Management LP now owns 9,344,424 shares of the company’s stock worth $38,873,000 after purchasing an additional 1,155,476 shares during the last quarter. Mirabella Financial Services LLP purchased a new position in shares of MaxCyte in the fourth quarter worth about $15,392,000. River Global Investors LLP boosted its position in MaxCyte by 57.7% during the fourth quarter. River Global Investors LLP now owns 3,253,192 shares of the company’s stock worth $13,494,000 after acquiring an additional 1,190,630 shares during the last quarter. Mudita Advisors LLP grew its stake in MaxCyte by 2.2% during the 4th quarter. Mudita Advisors LLP now owns 3,223,407 shares of the company’s stock valued at $13,409,000 after acquiring an additional 69,966 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in MaxCyte by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 2,474,632 shares of the company’s stock valued at $9,628,000 after acquiring an additional 47,960 shares during the last quarter. 68.81% of the stock is currently owned by hedge funds and other institutional investors.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.